Olympus AI Stock Analysis
Want to see OLYMY full AI Analyst Report?
Olympus (OLYMY) AI Stock Analysis
Olympus
(Other OTC:OLYMY)
The score is primarily supported by solid financial performance (strong margins, modestly improving growth, and a TTM rebound in free cash flow), but is held back by weaker technical momentum (below key moving averages with negative MACD) and only moderate valuation support (P/E ~25 with a ~1.4% yield).
Olympus (OLYMY) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $11.77B
- Dividend Yield
- 1.41%
- Average Volume (3M)
- 21.31K
- Price to Earnings (P/E)
- 21.1
- Beta (1Y)
- 0.33
- Revenue Growth
- 3.54%
- EPS Growth
- -7.45%
- Country
- US
- Employees
- 28,138
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
Olympus Business Overview & Revenue Model
Company Description
Olympus Corporation, alongside its affiliated companies, operates as a global enterprise specializing in the development and distribution of medical equipment. Its reach extends across Japan, the Americas, the Middle East, Asia, and Oceania. The comp...
How the Company Makes Money
Olympus primarily makes money by selling medical device systems and the recurring products and services that accompany them. Key revenue streams include: (1) Capital equipment sales: one-time sales of endoscopy towers/visualization systems, video pro...
Olympus Earnings Call Summary
The call balanced significant near-term operational and regulatory challenges (FDA observations, product ship holds, one-off gross margin/COGS impacts, and increased restructuring provisioning) against clear signs of stabilization and management actions (China recovery, majority of products released, leadership changes, disciplined commercial remediation and maintained mid-term targets). Management emphasized these are addressable, one-off or execution-related issues and reiterated long-term margin and growth ambitions, but material short-term impacts keep the tone cautious.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Management revised constant‑currency revenue guidance down ~2% and framed near‑term outlook as a range (reflecting the dynamic timing of product releases), while reaffirming its midterm targets of mid‑single‑digit revenue growth and a 20%+ operating margin; key metrics called out included the company’s “3–4–5” mid‑range modeling with 100+ basis points of margin improvement annually from FY27, inspections at 8 facilities (U.S., Europe, Japan) with ~70% of ship‑hold products already released and ~30% still being remediated, an expected Q4 revenue impact from ship holds of about JPY 18 billion, structural‑reform costs provisioned at JPY 31 billion (revised up from JPY 12 billion) with ~90% booked this fiscal year and the previously announced JPY 24 billion reduction effect unchanged, China showing a recovery (management cited roughly 6% Q3 growth and expects mid‑single‑digit market growth), and that one‑time COGS pressure from disposals/field corrective actions drove the gross‑margin hit rather than a fundamental mix shift.
Olympus Financial Statement Overview
Summary
Fundamentals are solid but not top-tier: strong TTM profitability (≈64.7% gross margin, ≈11.2% operating margin, ≈7.5% net margin) and improved revenue growth (~2.0% TTM vs ~1.3% annual). Offsetting this are uneven earnings/cash-flow quality across years (including negative FCF in FY2024) and a meaningful rise in total debt from the latest annual period to TTM.
Income Statement
74PositiveBalance Sheet
70PositiveCash Flow
67Positive| Breakdown | TTM | Mar 2026 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.06T | 1.01T | 997.33B | 925.75B | 881.92B | 750.12B |
| Gross Profit | 701.15B | 654.09B | 683.70B | 618.43B | 596.85B | 506.70B |
| EBITDA | 239.47B | 170.51B | 232.37B | 119.85B | 219.64B | 143.12B |
| Net Income | 90.53B | 68.17B | 117.86B | 242.57B | 115.97B | 115.74B |
Balance Sheet | ||||||
| Total Assets | 1.52T | 1.54T | 1.43T | 1.53T | 1.36T | 1.18T |
| Cash, Cash Equivalents and Short-Term Investments | 189.84B | 216.46B | 254.83B | 350.80B | 312.84B | 227.75B |
| Total Debt | 336.51B | 239.58B | 229.10B | 299.62B | 386.13B | 355.26B |
| Total Liabilities | 766.48B | 725.12B | 681.09B | 777.03B | 846.64B | 785.54B |
| Stockholders Equity | 755.41B | 812.04B | 751.73B | 757.19B | 510.17B | 394.33B |
Cash Flow | ||||||
| Free Cash Flow | 90.30B | 18.16B | 125.25B | -22.26B | 107.96B | 64.89B |
| Operating Cash Flow | 142.19B | 100.58B | 190.46B | 42.37B | 169.73B | 124.12B |
| Investing Cash Flow | -119.49B | -87.41B | -65.47B | 359.99B | -71.02B | -118.92B |
| Financing Cash Flow | -14.66B | -87.63B | -211.54B | -276.01B | -40.67B | 40.80B |
Olympus Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OLYMY, the sentiment is Negative. The current price of 11.11 is above the 20-day moving average (MA) of 11.04, below the 50-day MA of 11.94, and above the 200-day MA of 11.07, indicating a neutral trend. The MACD of -0.21 indicates Negative momentum. The RSI at 45.34 is Neutral, neither overbought nor oversold. The STOCH value of 22.18 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for OLYMY.
Olympus Peers Comparison
Overall Rating
MDT81Outperform
GEHC79Outperform
SYK75Outperform
SNN69Neutral
PHG67Neutral- OLYMY63Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| MDT | 81Outperform | $131.58B | 25.15 | 10.60% | 2.78% | 9.77% | 12.28% |
| GEHC | 79Outperform | $37.54B | 17.51 | 19.85% | 0.17% | 6.87% | -2.26% |
| SYK | 75Outperform | $117.88B | 32.77 | 15.61% | 1.14% | 7.87% | 22.82% |
| SNN | 69Neutral | $13.01B | 20.45 | 12.25% | 2.54% | 5.26% | 31.02% |
| PHG | 67Neutral | $29.39B | 27.22 | 8.44% | 3.26% | ― | ― |
| OLYMY | 63Neutral | $12.24B | 21.10 | 11.80% | 1.41% | 3.54% | -7.45% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| OLYMY | Olympus Corp. Adr | 11.11 | -2.20 | -16.51% | |
| PHG | Koninklijke Philips N.V. | 30.34 | 3.25 | 12.01% | |
| MDT | Medtronic | 102.86 | 9.67 | 10.38% | |
| SNN | Smith & Nephew Snats | 31.28 | -0.46 | -1.45% | |
| SYK | Stryker Corp | 309.64 | -46.54 | -13.07% | |
| GEHC | Ge Healthcare Technologies Inc. | 83.02 | 12.53 | 17.78% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 11, 2026